A Study of Itraconazole in the Management of Superficial Fungal Infections in India

Phase 4TerminatedNCT03923010

Janssen Research & Development, LLC40 enrolled

Overview

The purpose of this study is to estimate the proportion of participants prescribed itraconazole for Tinea cruris or Tinea corporis who have clinical response after 7 days of treatment.

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Mycoses

Interventions

ItraconazoleDRUG

Participants will receive itraconazole 200 mg orally once daily for 7 days and at the discretion of the treating physician on Day 14. Participants will also get their regular clinical care at the discretion of their treating physician.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinically diagnosed with Tinea cruris or Tinea corporis with or without history of treatment * Are prescribed itraconazole at 200 milligram/day orally for the treatment of T. cruris or T. corporis and taken once a day * A woman of childbearing potential must have a negative highly sensitive serum (beta human chorionic gonadotropin \[beta hCG\]) at screening on Day -3 to 0 before start of study drug * A woman must be (a) not of childbearing potential (b) of childbearing potential and: Practicing a highly effective method of contraception (failure rate of less than \[\<\] 1 percentage \[%\] per year when used consistently and correctly) and agrees to remain on a highly effective method while receiving study drug and until 30 days after last dose (that is, the end of relevant systemic exposure) * A male participant must wear a condom when engaging in any activity that allows for passage of ejaculate to another person. A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum 90 days after receiving the last dose of study drug Exclusion Criteria: * History of ventricular dysfunction such as congestive heart failure (CHF) or receiving treatment for CHF, liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances at any time prior to the start of study * Known achlorhydria or on treatment of gastric acidity * Presence of other dermatoses, example. psoriasis, seborrhoeic or atopic dermatitis * Infected with organism with known or established resistance to itraconazole * Co-existing fungal infection of other body area

Locations (4)

Post Graduate Institute of Medical Education & Research (PGIMER)

Chandigarh, India

Sri Ramachandra Medical Centre

Chennai, India

Yenepoya Medical College

Mangalore, India

Lata Mangeshkar Hospital

Nagpur, India

Outcomes

Primary Outcomes

Percentage of Participants with Clinical Response

Percentage of participants with clinical response will be reported. Assessment of clinical response will be done by using Investigator Global Evaluation tool based on the signs and symptoms and clinical improvement scores. The percentage of clinical improvement will be measured at the score ranging from 1 to 5 where Score 1: Healed (absence of signs and symptoms), Score 2: Markedly improved (greater than \[\>\] 50 percentage \[%\] clinical improvement), Score 3: Considerable residual lesion (less than \[\<\] 50% clinical improvement), Score 4: No change (same as baseline), and Score 5: Worse (deterioration from baseline). Clinical response will be defined as having Scores 1 or 2 (healed or markedly improved).

Time frame: Day 7 (End of Treatment)

Secondary Outcomes

Percentage of Participants who Have Mycological Cure

Percentage of participants who have mycological cure will be reported. Mycological cure is defined as both culture and microscopy negative to causative fungi.

Time frame: Day 14

Plasma Concentrations of Itraconazole and Hydroxy-Itraconazole

Plasma concentrations of itraconazole and hydroxy-itraconazole will be measured.

Time frame: Days 7 and 14: Pre-dose, 2 and 4.5 hours

Baseline Minimum Inhibitory Concentration (MIC) of Itraconazole

Minimum inhibitory concentration of itraconazole toward fungal pathogens will be determined.

Time frame: Baseline (Day 0)

Percentage of Participants with Clinical Response

Percentage of participants with clinical response will be reported. Assessment of clinical response will be done by using Investigator Global Evaluation tool based on the signs and symptoms and clinical improvement scores. The percentage of clinical improvement will be measured at the score ranging from 1 to 5 where Score 1: Healed (Absence of signs and symptoms), Score 2: Markedly improved (greater than \[\>\] 50 percentage \[%\] clinical improvement), Score 3: Considerable residual lesion (less than \[\<\] 50% clinical improvement), Score 4: No change (same as baseline), and Score 5: Worse (deterioration from baseline). Clinical response will be defined as having Scores 1 or 2 (healed or markedly improved).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.